127 / 140
Principios generales de tratamiento particularizado de los sarcomas de partes blandas según histología
>
127
82. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with
relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for
research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol
2009;27:3126-32.
83. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and
figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011;17:871-9.
Fibrosarcoma y sus variantes
Dermatofibrosarcoma
protuberans
84. Lemm D, Mügge LO, Mentzel T, et al. Current treatment options in dermatofibrosarcoma protuberans. J Can-
cer Res Clin Oncol 2009;135:653-65.
85. Antony Ng, Nishikawa H, Lander A, et al. Chemosensitivity in Pediatric Dermatofibrosarcoma Protuberans.
J Pediatr Hematol Oncol 2005;27:100-2.
86. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib
mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-91.
87. Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma
arising from dermatofibrosarcoma protuberans. Int J Cancer 2002;100:623-6.
88. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced der-
matofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
J Clin Oncol 2005;23:866-73.
Fibrosarcoma del adulto
89. Okuno S, Bailey H, Mahoney M, et al. A Phase 2 Study of Temsirolimus (CCI-779) in Patients With Soft Tis-
sue Sarcomas A Study of the Mayo Phase 2 Consortium (P2C). Cancer 2011;117(15):3468-75.
Sarcomas vasculares
Hemangioendotelioma epiteloide
90. Idilman R, Dokmeci A, Beyler AR, et al. Successful medical treatment of an epithelioid hemangioendothelio-
ma of liver. Oncology 1997;54:171-5.
91. Kelly H, O’Neil BH. Response of epithelioid haemangioendothelioma to liposomal doxorubicin. Lancet Oncol
2005;6:813-5.
92. Grenader T, Vernea F, Reinus C, et al. Malignant Epithelioid Hemangioendothelioma of the Liver Successful
treated with Pegylated Lyposomal Doxorrubicin. J Clin Oncol 2011;29:e722-e724.
93. Pintoffl J, Meisinger I, Mayer F, et al. Long-term disease stabilization during second-line gemcitabine in a
refractory metastatic haemangioendothelioma. January 2009;20(1):73-4.
94. Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the
treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013;24:257-63.
95. Chevreau C, Le Cesne A, Ray-Coquard I, et al. Sorafenib in Patients With Progressive Epithelioid Hemangio-
endothelioma. A Phase 2 Study by the French Sarcoma Group (GSF/GETO). Cancer 2013;119:2639-44.
96. Kayler LK, Merion RM, Arenas JD, et al. Epithelioid hemangioendothelioma of the liver disseminated to the
peritoneum treated with liver transplantation and interferon alpha-2B. Transplantation 2002;74:128-30.
97. Radzikowska E, Szczepulska-Wojcik E, Chabowski M, et al. Pulmonary epithelioid hemangioendothelioma-
interferon 2-alpha treat- ment-case report. Pneumol Alergol Pol 2008;76:281-5.
98. Mascarenhas RC, Sanghvi AN, Friedlander L, et al. Thalidomide inhibits the growth and progres- sion of he-
patic epithelioid hemangioendothelioma. Oncology 2004;67:471-5.
99. Raphael C, Hudson E, Williams L, et al. Successful treatment of metastatic hepatic epithelioid hemangioendo-
thelioma with thamidomide: a case report [serial online]. J Med Case Rep 2010;4:413.